GLP-1 Advisor | One Day MD

Evidence review: November 3, 2026 | Audience: United States Peptides have become increasingly popular in longevity medicine, regenerative health and aesthetic dermatology. From copper peptides such as GHK-Cu to experimental mitochondrial peptides such as MOTS-c and telomere-related compounds such as Epitalon, these molecules are being investigated for their potential effects on skin aging, cellular function, tissue repair and metabolic health. But which peptides actually have evidence behind them? Which may support collagen production? And which are being marketed as longevity treatments without sufficient human clinical evidence? The distinction matters. A peptide that stimulates collagen-related pathways in laboratory experiments does not necessarily produce visible skin improvements in people. Similarly, a compound that changes a cellular aging biomarker does not necessarily extend human lifespan. This guide compares the most discussed peptides for longevity and colla...

By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: August 2026 Quick Answer Most content ranking for "injectable peptides for anti-aging" actually describes topical cosmetic peptides (Matrixyl, Argireline, copper peptide serums) that are never injected at all. True injectable anti-aging peptides fall into distinct categories: skin-quality "boosters" used in medical aesthetics (injectable GHK-Cu, growth-factor mesotherapy), growth-hormone secretagogues (sermorelin, tesamorelin, CJC-1295, ipamorelin), regenerative peptides (BPC-157, TB-500), and cellular/metabolic peptides (MOTS-c, epitalon). Evidence quality varies enormously — from large randomized trials (tesamorelin, GLP-1 drugs) down to animal-only data (BPC-157, most "longevity" peptides). As of August 2026, several popular peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon) were recommended by an FDA advisory panel for legal compounding but are not yet...

Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide and CagriSema: what is and isn't known Do GLP-1s slow biological aging? Safety, side effects and compounding risks Compounded, gray-market and research peptides: what are the r...